Related Experiment Video

Updated: Sep 24, 2025

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.8K

CILP1 as a biomarker for right ventricular dysfunction in patients with ischemic cardiomyopathy

Stanislav Keranov1,2, Leili Jafari1, Saskia Haen1

  • 1Department of Internal Medicine I, Cardiology and Angiology Justus-Liebig-University Giessen Germany.

Pulmonary Circulation
|May 4, 2022
PubMed

Insights

Cartilage intermediate layer protein 1 (CILP1) shows promise as a biomarker for right ventricular dysfunction in ischemic cardiomyopathy (ICM). Higher CILP1 levels correlate with reduced right ventricular ejection fraction, indicating its potential role in assessing cardiac health.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Cardiac Imaging

Background:

  • Ischemic cardiomyopathy (ICM) frequently leads to right ventricular (RV) dysfunction.
  • Accurate biomarkers for RV dysfunction in ICM are crucial for prognosis and management.
  • Existing biomarkers may not fully capture the extent of RV impairment.

Purpose of the Study:

  • To investigate cartilage intermediate layer protein 1 (CILP1) as a potential biomarker for RV dysfunction in patients with ICM.
  • To correlate CILP1 plasma concentrations with RV and left ventricular (LV) function parameters.
  • To assess the predictive value of CILP1 for RV dysfunction using receiver-operating characteristic (ROC) analysis.

Main Methods:

  • Plasma CILP1 concentrations were measured in 98 ICM patients and 30 controls.
  • Cardiac magnetic resonance imaging (CMR) was performed to assess RV and LV function.
  • Statistical analyses included tertile analysis, ROC analysis, and multivariable regression.

Main Results:

  • Median CILP1 levels were significantly higher in ICM patients compared to controls.
  • Higher CILP1 concentrations were associated with lower right ventricular ejection fraction (RVEF) and higher RV end-systolic volume index in ICM.
  • CILP1 demonstrated predictive value for RVEF < 40% (AUC = 0.72), comparable to NT-proBNP (AUC = 0.77).
  • RVEF was the sole independent predictor of elevated CILP1, while CILP1 and LVEF predicted RVEF < 40% in ICM.

Conclusions:

  • CILP1 may serve as a novel cardiac biomarker for prognostically relevant RV dysfunction in ICM.
  • CILP1 levels are associated with impaired RV function in ICM patients.
  • Further research is warranted to validate CILP1's clinical utility in managing ICM-related RV dysfunction.

Keywords:
MRIRVEFfibrosismyocardial remodeling

More Related Videos

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.9K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
50
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
236
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
73
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
39